Antipsychotic-induced weight gain in first-episode psychosis patients: a meta-analysis of differential effects of antipsychotic medications

Neocortical serotonin2A receptor binding predicts quetiapine associated weight gain in antipsychotic-naive first-episode schizophrenia patients

(2014) Hans Rasmussen et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

An Exploratory Randomized Controlled Study of a Healthy Living Intervention in Early Intervention Services for Psychosis

(2014) Karina Lovell et al.   JOURNAL OF CLINICAL PSYCHIATRY

Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis

(2014) Maarten Bak et al.   PLoS One

Retracted: Long-term efficacy and safety of blonanserin in patients with first-episode schizophrenia: A 1-year open-label trial

(2014) Yuriko Ninomiya et al.   PSYCHIATRY AND CLINICAL NEUROSCIENCES

Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12weeks of treatment in first treated episode of psychosis

(2014) Rocio Pérez-Iglesias et al.   SCHIZOPHRENIA RESEARCH

The Role of Hypothalamic H1 Receptor Antagonism in Antipsychotic-Induced Weight Gain

(2013) Meng He et al.   CNS DRUGS

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

(2013) Stefan Leucht et al.   LANCET

A Behavioral Weight-Loss Intervention in Persons with Serious Mental Illness

(2013) Gail L. Daumit et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized trial of clozapine vs. risperidone in treatment-naïve first-episode schizophrenia: Results after one year

(2013) Javier Sanz-Fuentenebro et al.   SCHIZOPHRENIA RESEARCH

Cardiovascular mortality in schizophrenia: Defining a critical period for prevention

(2013) Vinod H. Srihari et al.   SCHIZOPHRENIA RESEARCH

Efficacy and safety of ziprasidone in the treatment of first-episode psychosis

(2012) Tong Zhao et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial

(2012) W. Wolfgang Fleischhacker et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Contingency Management for the Treatment of Antipsychotic-Induced Weight Gain: A Randomized Controlled Pilot Study

(2012) Joseph C. Ratliff et al.   Obesity Facts

Cardiovascular morbidity, mortality and pharmacotherapy in patients with schizophrenia

(2012) M. Lahti et al.   PSYCHOLOGICAL MEDICINE

Comparison of metabolic effects of ziprasidone versus olanzapine treatment in patients with first-episode schizophrenia

(2012) Jian-Jun Ou et al.   PSYCHOPHARMACOLOGY

Obese Schizophrenia Spectrum Patients Have Significantly Higher 10-Year General Cardiovascular Risk and Vascular Ages than Obese Individuals without Severe Mental Illness

(2012) Joseph C. Ratliff et al.   PSYCHOSOMATICS

A Randomized Trial Examining the Effectiveness of Switching From Olanzapine, Quetiapine, or Risperidone to Aripiprazole to Reduce Metabolic Risk: Comparison of Antipsychotics for Metabolic Problems (CAMP)

(2011) T. Scott Stroup et al.   AMERICAN JOURNAL OF PSYCHIATRY

Early intervention with second-generation antipsychotics in first-episode psychosis: results of an 8-week naturalistic study

(2010) Richard C. Josiassen et al.   Early Intervention in Psychiatry

Association of Prescription H1 Antihistamine Use With Obesity: Results From the National Health and Nutrition Examination Survey

(2010) Joseph C. Ratliff et al.   Obesity

Trial of aripiprazole in the treatment of first-episode schizophrenia

(2010) Hwa-Young Lee et al.   PSYCHIATRY AND CLINICAL NEUROSCIENCES

Low prevalence of obesity and metabolic syndrome in never-treated chronic schizophrenia

(2010) Ramachandran Padmavati et al.   SCHIZOPHRENIA RESEARCH

Efficacy and Tolerability of Aripiprazole in First-Episode Drug-Naive Patients With Schizophrenia

(2009) Hitoshi Takahashi et al.   CLINICAL NEUROPHARMACOLOGY

Antipsychotic-Induced Weight Gain in Chronic and First-Episode Psychotic Disorders

(2009) Mario Álvarez-Jiménez et al.   CNS DRUGS

The unchanging mortality gap for people with schizophrenia

(2009) Lydia A Chwastiak et al.   LANCET

11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)

(2009) Jari Tiihonen et al.   LANCET

Metabolic side effects of antipsychotic drug treatment – pharmacological mechanisms

(2009) Gavin P Reynolds et al.   PHARMACOLOGY & THERAPEUTICS

The role of histaminergic H1 and H3 receptors in food intake: A mechanism for atypical antipsychotic-induced weight gain?

(2009) Chao Deng et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Weight gain in antipsychotic-naive patients: a review and meta-analysis

(2009) I. Tarricone et al.   PSYCHOLOGICAL MEDICINE

Ziprasidone Vs Olanzapine in Recent-Onset Schizophrenia and Schizoaffective Disorder: Results of an 8-Week Double-Blind Randomized Controlled Trial

(2009) K. P. Grootens et al.   SCHIZOPHRENIA BULLETIN

Metabolic profiles of second-generation antipsychotics in early psychosis: Findings from the CAFE study

(2009) Jayendra K. Patel et al.   SCHIZOPHRENIA RESEARCH

Olanzapine orally disintegrating tablets (Zyprexa ZydisR) rapidly improve excitement components in the acute phase of first-episode schizophrenic patients: An open-label prospective study

(2009) Hikaru Hori et al.   WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY

Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: Findings of a randomized clinical trial in a drug-naïve population

(2007) Rocio Perez-Iglesias et al.   SCHIZOPHRENIA RESEARCH